Standard BioTools Inc.
LAB
$1.29
-$0.04-3.01%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.25% | -6.61% | 65.74% | 77.27% | -18.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.25% | -6.61% | 65.74% | 77.27% | -18.70% |
| Cost of Revenue | -8.12% | -13.69% | 67.30% | 52.73% | -40.15% |
| Gross Profit | 2.45% | 0.22% | 64.00% | 108.54% | 39.85% |
| SG&A Expenses | 13.05% | 12.91% | 76.02% | 54.33% | 10.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.80% | -0.48% | 77.41% | 61.56% | 3.21% |
| Operating Income | -9.06% | -5.30% | -99.49% | -38.78% | -43.13% |
| Income Before Tax | 28.04% | -44.18% | -69.53% | -28.04% | -51.77% |
| Income Tax Expenses | -1,661.54% | -205.31% | 267.90% | 136.00% | -87.04% |
| Earnings from Continuing Operations | 30.54% | -42.47% | -72.29% | -28.29% | -49.32% |
| Earnings from Discontinued Operations | 22.14% | 83.10% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.81% | 19.04% | -72.29% | -28.29% | -168.30% |
| EBIT | -9.06% | -5.30% | -99.49% | -38.78% | -43.13% |
| EBITDA | -13.71% | -12.59% | -134.39% | -126.32% | -20.71% |
| EPS Basic | 28.42% | 74.12% | 63.31% | 72.67% | 43.31% |
| Normalized Basic EPS | 5.65% | 6.34% | 51.37% | 76.12% | 75.39% |
| EPS Diluted | 28.42% | 74.12% | 64.03% | 73.15% | 43.31% |
| Normalized Diluted EPS | 5.65% | 6.34% | 51.37% | 76.12% | 75.39% |
| Average Basic Shares Outstanding | 2.19% | 28.60% | 369.77% | 369.40% | 373.29% |
| Average Diluted Shares Outstanding | 2.19% | 28.60% | 369.77% | 369.40% | 373.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |